Recent Updates
Recently added Catalysts
RYTM

Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE setmelanotide for the Treatment of Obesity and Control of Hunger Associated with POMC PCSK1 and LEPR

Friday, July 23, 2021 1 min read
Key Takeaway: Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE setmelanotide for the Treatment of Obesity and Control of Hunger Associated with POMC PCSK1 and LEPR

Full Press Release Details

Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE setmelanotide for the Treatment of Obesity and Control of Hunger Associated with POMC PCSK1 and LEPR.
Tags: RYTM Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 23, 2021